



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Product Information



LPA₃ Blocking Peptide

Item No. 10005092

Lysophosphatidic acid receptor 3 (LPA₃; also known as edg-7) is one of three LPA receptors (LPA₁, LPA₂, and LPA₃) that are members of large family of GPCRs that also include those for sphingosine-1-phosphate (SIP₁₋₅).¹ The LPA receptors mediate many cellular responses including cytoskeletal rearrangements, cell proliferation, and inhibition of gap junction communication.^{2,3} Murine and human LPA₃ has 353 amino acids with an estimated molecular weight of 40 kDa.^{4,5} The mRNA level of LPA₃ is high in testes, kidney, and lung but low in intestine, heart, thymus, and stomach.⁵ Cayman's LPA₃ polyclonal antibody detects a protein at around 40 kDa in human HepG2 cells, murine macrophages, and in murine and rat liver.

Laboratory Procedures

This vial contains 200 µg peptide in 200 µl TBS, pH 7.4, containing 0.1% BSA and 0.02% sodium azide. The LPA₃ Blocking Peptide (Murine LPA₃ amino acids 1-12) can be used in conjunction with Cayman's LPA₃ Polyclonal Antibody (Item No. 10004840) to block protein-antibody complex formation during immunochemical analysis of LPA₃.

Store this peptide solution at -20°C. It will be stable for at least two years. To block antibody/protein complex formation, the following procedure is recommended:

1. Mix the LPA₃ Polyclonal Antibody (Item No. 10004840) and blocking peptide together in a 1:1 (v/v) ratio in a microfuge tube. For example, mix 20 µl of antibody and 20 µl of peptide.*
2. Incubate for one hour at room temperature with occasional mixing prior to further dilution and application of the mixture to the immunoblot.
3. Dilute the mixture to the final working antibody concentration and apply to the slide or membrane as usual.

*This is a recommended mixture. The minimum amount of peptide needed for complete blocking has not been precisely determined and may vary depending on the sample being analyzed. The amount of peptide required may need to be increased if sufficient blocking does not occur.

References

1. Chun, J., Goetzl, E.J., Hla, T., *et al.* International union of pharmacology. XXXIV. Lysophospholipid receptor nomenclature. *Pharmacol. Rev.* **54**, 265-269 (2002).
2. Fukushima, N. and Chun, J. The LPA receptors. *Prostaglandins and Other Lipid Mediators* **64**, 21-32 (2001).
3. Contos, J.J.A., Ishii, I., and Chun, J. Lysophosphatidic Acid Receptors. *Mol. Pharmacol.* **58**, 1188-1196 (2000).
4. Bandoh, K., Aoki, J., Hosono, H., *et al.* Molecular cloning and characteristics of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. *J. Biol. Chem.* **274**(39), 27776-27785 (1999).
5. Contos, J.J.A. and Chun, J. The mouse lpA₃/Edg7 lysophosphatidic acid receptor gene: genomic structure, chromosomal localization, and expression pattern. *Gene* **267**, 243-253 (2001).

Related Products

For a list of related products please visit: www.caymanchem.com/catalog/10005092

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

MATERIAL SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Material Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman warrants only to the original customer that the material will meet our specifications at the time of delivery.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have any obligation or liability, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's **exclusive remedy** and Cayman's sole liability hereunder shall be limited to a **refund** of the purchase price, or at Cayman's option, the **replacement**, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

Copyright Cayman Chemical Company, 07/18/2012

Cayman Chemical

Mailing address

1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone

(800) 364-9897
(734) 971-3335

Fax

(734) 971-3640

E-Mail

custserv@caymanchem.com

Web

www.caymanchem.com